Drug intelligence / Profile preview

HTF1037

Development stage: Unknown
Lead developer: HighTide Therapeutics
Modality: Small Molecules

Overview

HTF1037 is a mitochondrial uncoupler being developed by HighTide Therapeutics for the treatment of obesity. It works by disrupting the normal coupling between nutrient oxidation and adenosine triphosphate (ATP) production within the mitochondria. By dissipating the proton gradient across the inner mitochondrial membrane, the drug increases metabolic fuel consumption and energy expenditure without a corresponding increase in ATP synthesis, potentially leading to significant weight loss. As of August 2025, HTF1037 is in Phase 1 clinical development.

Beyond the preview

Go deeper on HTF1037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTF1037.

Explore the full profile